News

TD-1473 is a novel, potent, orally administered and intestinally restricted pan-Janus kinase (JAK) inhibitor in clinical development, with the potential to treat a range of inflammatory intestinal diseases.

Under terms of the agreement, Daiichi Sankyo and AgonOx will collaborate on preclinical development of the program. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research,

The deal grants Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (‘the licensed territory’), to Summit’s utrophin modulator pipeline, including its lead

GCA is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries, most often in the head, but also in the aorta and its

Ohsumi used baker's yeast to find how cells recycle their content, a process known as autophagy, a Greek term for self-eating. The official website of the Nobel Prize

The $12.9m Series A round of funding was led by leading deep technology investor Lux Capital, with participation from Obvious Ventures, Epic Ventures, Data Collective, AME Cloud Ventures, Wild

The EC has also approved the transfer of the orphan designation to Sobi. As MAH, Sobi will assume full regulatory responsibility for Alprolix in the EU. The EC

Osimertinib which was only licensed in February this year is recommended in draft guidance to treat a particularly aggressive form of lung cancer. Earlier this year, NICE said

The company unveiled new data demonstrating Cosentyx delivers high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis out to four years of treatment. The data shows